- Sales of treatments for breast cancer are expected to increase an average of 5.8% per year, from $9.8 billion in 2013 to $18.2 billion by 2023, according to data from nine major markets from IMS Health.
- The highest growing segment will be drugs to treat HER-2 positive subtypes of breast cancer. Another fast-growing segment will be drugs to treat triple-negative breast cancer.
- In 2012, 1.6 million women were diagnosed with breast cancer and 500,000 women died from it.
IMS Health looked at data from nine countries, including the US, France, Germany, Italy, Spain, the UK, Japan, China and Brazil. Based on data from those countries, 1.2 million women were treated for breast cancer in 2013 -- a number that is expected to increase to 1.4 million by 2023. Last year, products from Roche, AstraZeneca and Novartis comprised 70% of the total market. The advent of tamoxifen for hormone-positive breast cancer, as well as Roche’s Herception (trastuzumab), have revolutionized the treatment of breast cancer. More positive changes are on the way as biosimilars and new-generation drugs come to market. One of the best examples of new game-changing drugs is Roche’s Perjeta (pertuzumab), which recently presented efficacy data that has been hailed as “unprecedented.”